Kimberly-Clark Plunges 19% after $48.7B Kenvue Buy with $2.1B Synergies
Kimberly-Clark shares are down 19% over the past six months after announcing a $48.7 billion cash-and-stock acquisition of Kenvue. The deal promises $1.9 billion in cost synergies and $500 million in revenue synergies, reducing the effective multiple to 8.8x on anticipated $2.1 billion run-rate benefits.
1. Acquisition Details
Kimberly-Clark agreed to acquire Kenvue, the Tylenol-maker, for $48.7 billion in a mix of cash and stock, valuing Kenvue at 14.3x its most recent EBITDA.
2. Impact on Stock Price
Following the announcement, Kimberly-Clark shares have declined 19% over six months, reflecting investor concerns over integration risks, near-term margin pressure and the deal’s financing structure.
3. Synergies and Valuation
The company forecasts $1.9 billion in cost synergies and $500 million in revenue synergies, translating to $2.1 billion in run-rate benefits and lowering the effective acquisition multiple to 8.8x EBITDA.
4. Business Outlook
With a 4.88% dividend yield and stable demand for essential consumer products, Kimberly-Clark could see a valuation rebound as synergies materialize and margin growth resumes.